Trastuzumab (anti-HER2) combined with pertuzumab for HER2+ breast cancer — what is the rationale for combining two HER2-targeted antibodies with different binding epitopes?

• A Trastuzumab and pertuzumab both bind domain IV, providing synergistic receptor downregulation
• B The combination is used purely to reduce the dose of each antibody, minimizing cardiotoxicity
• C Pertuzumab enhances trastuzumab's internalization into tumor cells enabling intracellular drug delivery
• D Trastuzumab binds HER2 domain IV (near the transmembrane region), while pertuzumab binds domain II (dimerization arm) — pertuzumab sterically blocks HER2-HER3 heterodimerization while trastuzumab prevents HER2 shedding and activates ADCC; together they provide complementary dual blockade of HER2 signaling ✓

Explanation

Trastuzumab and pertuzumab are non-competing, complementary anti-HER2 antibodies. Trastuzumab binds HER2 domain IV (juxtamembrane region), preventing metalloprotease-mediated extracellular domain shedding and inhibiting downstream PI3K/AKT signaling, while also mediating ADCC. Pertuzumab binds domain II (the dimerization arm) of HER2, physically blocking HER2 from forming heterodimers — particularly the most active HER2-HER3 heterodimer (the dominant signaling complex in breast cancer). Together they achieve dual-domain, dual-mechanism blockade: pertuzumab prevents dimerization while trastuzumab stabilizes membrane-bound HER2 and recruits immune effectors. This complementarity is why the combination significantly improves progression-free and overall survival over trastuzumab alone.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.